Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its recent oral tetrahydrocannabinol (“THC”) absorption study THC-A21-1 revealed that DehydraTECH(TM)-THC delivered via oral ingestion required only 15 minutes to del...
--News Direct-- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes Kelowna, British Columbia – TheNewswire - October 13, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Co...
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, was featured in the latest episode of the “ Stock2Me Podcast ,” an IBN (InvestorBrandNetwork) solution to provide specialized content distribution via widespread syndication chann...
--News Direct-- - DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls Kelowna, British Columbia - TheNewswire – October 5, 2021 – Lexaria Bioscie...
(TheNewswire) Vancouver, British Columbia – TheNewswire - September 21, 2021. Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (the “ Company ” or “Lexston” ) is pleased to announce the acquisi...
KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that Chairman & CEO Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investmen...
Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms today announced it is formal...
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innov...
(TheNewswire) Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability Kelowna, British Columbia - TheNewswire - July 29, 2021 - Lexaria Bioscience Corp. (Nasdaq:...
(TheNewswire) Lexaria’s technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more Kelowna, British Columbia - TheNewswire – July 28, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (N...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...